Russian Biotech Company Generium has Begun Clinical Trials of a Gene Therapy for Duchenne Muscular Dystrophy

According to an article published by the GXPNEWS news portal, Russian biotech company Generium will begin work on gene therapy for the treatment of Duchenne muscular dystrophy.

Clinical studies for a therapy for Duchenne muscular dystrophy have begun at Sirius University and the Russian biotech business Generium. At a gathering at Novosibirsk State University, Dmitry Kudlai, a Member of the Russian Academy of Sciences, offered his perspectives.

There is no clinical trial information for the Duchenne muscular dystrophy gene therapy in the Russian State Drug Register yet. As DMD Warrior, we will be following these statements.

SourceGXPNEWS

LEAVE A REPLY

Please enter your comment!
Please enter your name here


Hot Topics

Related Articles